

Tumor-Node-Metastasis Staging of Pancreatic Adenoca

Ca-A Cancer Journal for Clinicians

58, 111-125

DOI: [10.3322/ca.2007.0012](https://doi.org/10.3322/ca.2007.0012)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Multidisciplinary management of resectable adenocarcinoma of the pancreatic head. Expert Review of Anticancer Therapy, 2008, 8, 1611-1621.	1.1	1
2	CT-Guided Biopsy of Perivascular Tumor Encasement Using Simultaneous IV Contrast Enhancement. American Journal of Roentgenology, 2009, 193, W283-W287.	1.0	5
3	Translational advances and novel therapies for pancreatic ductal adenocarcinoma: hope or hype?. Expert Reviews in Molecular Medicine, 2009, 11, e34.	1.6	6
4	Margin Positive Pancreaticoduodenectomy Is Superior to Palliative Bypass in Locally Advanced Pancreatic Ductal Adenocarcinoma. Journal of Gastrointestinal Surgery, 2009, 13, 1937-1947.	0.9	33
5	Does Portal-Superior Mesenteric Vein Invasion Still Indicate Irresectability for Pancreatic Carcinoma?. Annals of Surgical Oncology, 2009, 16, 817-825.	0.7	117
6	Long-Term Survival After Multidisciplinary Management of Resected Pancreatic Adenocarcinoma. Annals of Surgical Oncology, 2009, 16, 836-47.	0.7	435
7	Surgical resectability of pancreatic adenocarcinoma: CTA. Abdominal Imaging, 2010, 35, 471-480.	2.0	38
8	Intraoperative Ultrasonography of the Pancreas. Radiographics, 2010, 30, 1935-1953.	1.4	38
9	Pancreatic Cancer Cells Expressing Hypoxia-Inducible Factor-1 α Tend to Be Adjacent to Intratumoral Blood Vessels. European Surgical Research, 2010, 45, 134-137.	0.6	4
10	Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Annals of Oncology, 2010, 21, 441-447.	0.6	300
11	Identification of Susceptibility Loci in a Mouse Model of <i>KRAS</i> G12D-Driven Pancreatic Cancer. Cancer Research, 2010, 70, 8398-8406.	0.4	2
12	Metronomic Gemcitabine in Combination with Sunitinib Inhibits Multisite Metastasis and Increases Survival in an Orthotopic Model of Pancreatic Cancer. Molecular Cancer Therapeutics, 2010, 9, 2068-2078.	1.9	46
13	Protocolo de tallado, estudio e informe anatomopatol3gico de las piezas de duodenopancreatectom3a cef3lica por carcinoma de p3ncreas. Revista Espanola De Patologia, 2010, 43, 207-214.	0.6	7
14	CT and Fusion PET-CT for Diagnosis, Staging and Follow-Up. , 2010, , 703-729.		0
15	Different approaches to assessment of lymph nodes and surgical margin status in patients with ductal adenocarcinoma of the pancreas treated with pancreaticoduodenectomy. Pathology, 2010, 42, 138-146.	0.3	15
16	Polypeptide N-acetylgalactosaminyltransferase 6 expression in pancreatic cancer is an independent prognostic factor indicating better overall survival. British Journal of Cancer, 2011, 104, 1882-1889.	2.9	62
17	A study of Smad4, Smad6 and Smad7 in Surgically Resected Samples of Pancreatic Ductal Adenocarcinoma and Their Correlation with Clinicopathological Parameters and Patient Survival. BMC Research Notes, 2011, 4, 560.	0.6	12
18	Standardization of Surgical and Pathologic Variables is Needed in Multicenter Trials of Adjuvant Therapy for Pancreatic Cancer: Results from the ACOSOG Z5031 Trial. Annals of Surgical Oncology, 2011, 18, 337-344.	0.7	72

#	ARTICLE	IF	CITATIONS
19	Distal Pancreatectomy Combined with Celiac Axis Resection in Treatment of Carcinoma of the Body/Tail of the Pancreas: Proceed with Caution. <i>Annals of Surgical Oncology</i> , 2011, 18, 244-244.	0.7	1
20	Detection of Differentially Expressed microRNAs in Serum of Pancreatic Ductal Adenocarcinoma Patients: miR-196a Could Be a Potential Marker for Poor Prognosis. <i>Digestive Diseases and Sciences</i> , 2011, 56, 602-609.	1.1	144
21	Serum biomarkers for improved diagnostic of pancreatic cancer: a current overview. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011, 137, 375-389.	1.2	111
22	Imaging in Staging and Management of Pancreatic Ductal Adenocarcinoma. <i>Indian Journal of Surgical Oncology</i> , 2011, 2, 78-87.	0.3	2
23	Adenosquamous Versus Adenocarcinoma of the Pancreas: A Population-Based Outcomes Analysis. <i>Journal of Gastrointestinal Surgery</i> , 2011, 15, 165-174.	0.9	64
24	Heme oxygenase-1 germ line GTn promoter polymorphism is an independent prognosticator of tumor recurrence and survival in pancreatic cancer. <i>Journal of Surgical Oncology</i> , 2011, 104, 305-311.	0.8	21
25	Impact of omission of elective nodal irradiation on treatment outcomes in locally advanced pancreatic adenocarcinoma patients treated with definitive concurrent chemoradiotherapy. <i>Pancreatology</i> , 2012, 12, 434-439.	0.5	2
26	Losses at chromosome 4q are associated with poor survival in operable ductal pancreatic adenocarcinoma. <i>Pancreatology</i> , 2012, 12, 16-22.	0.5	9
27	Clinical Calculator of Conditional Survival Estimates for Resected and Unresected Survivors of Pancreatic Cancer. <i>Archives of Surgery</i> , 2012, 147, 513-9.	2.3	48
28	Metastatic lymph node ratio as an important prognostic factor in pancreatic ductal adenocarcinoma. <i>European Journal of Surgical Oncology</i> , 2012, 38, 333-339.	0.5	59
29	Heat shock protein 27 as a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2012, 16, 1776-1791.	1.6	38
30	PDGFR β expression in tumor stroma of pancreatic adenocarcinoma as a reliable prognostic marker. <i>Medical Oncology</i> , 2012, 29, 2824-2830.	1.2	59
31	Pancreatic Carcinoma Cell Lines Reflect Frequency and Variability of Cancer Stem Cell Markers in Clinical Tissue. <i>European Surgical Research</i> , 2012, 49, 88-98.	0.6	19
32	Irrelevance of Microsatellite Instability in the Epidemiology of Sporadic Pancreatic Ductal Adenocarcinoma. <i>PLoS ONE</i> , 2012, 7, e46002.	1.1	63
33	Pancreas and liver. , 0, , 242-266.		0
34	Pancreatic cancer: surgical management and outcomes after 6 years of follow-up. <i>Medical Journal of Australia</i> , 2012, 196, 511-515.	0.8	43
35	Low Expression of IGFBP7 is Associated with Poor Outcome of Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2012, 19, 3971-3978.	0.7	30
36	Is celiac axis resection justified for T4 pancreatic body cancer?. <i>Surgery</i> , 2012, 151, 61-69.	1.0	74

#	ARTICLE	IF	CITATIONS
37	Defined Clinical Classifications Are Associated with Outcome of Patients with Anatomically Resectable Pancreatic Adenocarcinoma Treated with Neoadjuvant Therapy. <i>Annals of Surgical Oncology</i> , 2012, 19, 2045-2053.	0.7	96
38	Effect of Neoadjuvant Chemoradiation and Surgical Technique on Recurrence of Localized Pancreatic Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2012, 16, 68-79.	0.9	98
39	Clinical utility of high-throughput glycome analysis in patients with pancreatic cancer. <i>Journal of Gastroenterology</i> , 2013, 48, 1171-1179.	2.3	48
40	Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9. <i>BMC Cancer</i> , 2013, 13, 404.	1.1	45
41	Expression of CD44v6 and integrin- α 1 for the prognosis evaluation of pancreatic cancer patients after cryosurgery. <i>Diagnostic Pathology</i> , 2013, 8, 146.	0.9	13
42	Neoadjuvant therapy for resectable and borderline resectable pancreatic cancer. <i>Journal of Radiation Oncology</i> , 2013, 2, 353-367.	0.7	4
43	Biglycan expression and clinical outcome in patients with pancreatic adenocarcinoma. <i>Tumor Biology</i> , 2013, 34, 131-137.	0.8	49
44	Number of examined lymph nodes and nodal status assessment in pancreaticoduodenectomy for pancreatic adenocarcinoma. <i>European Journal of Surgical Oncology</i> , 2013, 39, 1116-1121.	0.5	43
45	Artificial neural networks predict survival from pancreatic cancer after radical surgery. <i>American Journal of Surgery</i> , 2013, 205, 1-7.	0.9	37
46	Neoplasms of the pancreas. <i>Imaging</i> , 2013, 22, 20369618.	0.0	0
47	Neoadjuvant therapy in borderline resectable pancreatic ductal adenocarcinoma: A single institution review. <i>Journal of Solid Tumors</i> , 2014, 4, .	0.1	1
48	The combination of a nuclear HMGB1-positive and HMGB2-negative expression is potentially associated with a shortened survival in patients with pancreatic ductal adenocarcinoma. <i>Tumor Biology</i> , 2014, 35, 10555-10569.	0.8	10
49	Feasibility and Safety of Intraoperative Electrochemotherapy in Locally Advanced Pancreatic Tumor: A Preliminary Experience. <i>European Journal of Inflammation</i> , 2014, 12, 467-477.	0.2	12
50	Benefit from synchronous portal-superior mesenteric vein resection during pancreaticoduodenectomy for cancer: A meta-analysis. <i>European Journal of Surgical Oncology</i> , 2014, 40, 371-378.	0.5	109
51	Chemoradiation therapy sequencing for resected pancreatic adenocarcinoma in the National Cancer Data Base. <i>Cancer</i> , 2014, 120, 499-506.	2.0	39
52	Pearls and pitfalls of imaging metastatic disease from pancreatic adenocarcinoma: a systematic review. <i>Clinical Imaging</i> , 2015, 39, 750-758.	0.8	12
53	Diagnosis and Management of Borderline Resectable Pancreatic Adenocarcinoma. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 727-740.	0.9	19
54	Dual-energy CT of pancreatic adenocarcinoma: reproducibility of primary tumor measurements and assessment of tumor conspicuity and margin sharpness. <i>Abdominal Radiology</i> , 2016, 41, 1317-1324.	1.0	31

#	ARTICLE	IF	CITATIONS
55	The lymphatic system and pancreatic cancer. <i>Cancer Letters</i> , 2016, 381, 217-236.	3.2	44
56	Pancreatectomy with Mesenteric and Portal Vein Resection for Borderline Resectable Pancreatic Cancer: Multicenter Study of 406 Patients. <i>Annals of Surgical Oncology</i> , 2016, 23, 2028-2037.	0.7	67
57	Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1338.	1.8	431
58	Knockdown of pseudogene derived from lncRNA DUXAP10 inhibits cell proliferation, migration, invasion, and promotes apoptosis in pancreatic cancer. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 3671-3682.	1.2	29
59	Evolution of pancreatectomy with en bloc venous resection for pancreatic cancer in Italy. Retrospective cohort study on 425 cases in 10 pancreatic referral units. <i>International Journal of Surgery</i> , 2018, 55, 103-109.	1.1	13
60	Routine portal vein resection for pancreatic adenocarcinoma shows no benefit in overall survival. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1094-1099.	0.5	12
61	Prognostic value of glypican-1 for patients with advanced pancreatic cancer following regional intra-arterial chemotherapy. <i>Oncology Letters</i> , 2018, 16, 1253-1258.	0.8	25
62	Phase Ib trial combining capecitabine, erlotinib and bevacizumab in pancreatic adenocarcinoma - REBECA trial. <i>Investigational New Drugs</i> , 2019, 37, 127-138.	1.2	0
63	Comparative characterization of the HGF/Met and MSP/Ron systems in primary pancreatic adenocarcinoma. <i>Cytokine</i> , 2019, 123, 154762.	1.4	7
64	Neo-adjuvant therapy for pancreatic cancer: hope for the future. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 579-589.	1.4	6
65	Clinicopathological and prognostic significance of MKK4 and MKK7 in resectable pancreatic ductal adenocarcinoma. <i>Human Pathology</i> , 2019, 86, 143-154.	1.1	8
66	Carcinoma of the Pancreas. , 2020, , 1342-1360.e7.		1
67	Intron retention is a robust marker of intertumoral heterogeneity in pancreatic ductal adenocarcinoma. <i>Npj Genomic Medicine</i> , 2020, 5, 55.	1.7	10
68	Applying a radiomics-based strategy to preoperatively predict lymph node metastasis in the resectable pancreatic ductal adenocarcinoma. <i>Journal of X-Ray Science and Technology</i> , 2020, 28, 1113-1121.	0.7	15
69	Of immune checkpoint maladies and remedies: The throwing of jabs in the oncogenic ring of PDAC. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1875, 188483.	3.3	7
70	Elevated TIAM2 expression promotes tumor progression and is associated with unfavorable prognosis in pancreatic cancer. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 59-67.	0.6	2
71	Clinicopathological and prognostic significance of ubiquitin-specific peptidase 15 and its relationship with transforming growth factor- α receptors in patients with pancreatic ductal adenocarcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 507-515.	1.4	7
72	The Role of Home-Based Exercise in Maintaining Skeletal Muscle During Preoperative Pancreatic Cancer Treatment. <i>Integrative Cancer Therapies</i> , 2021, 20, 153473542098661.	0.8	20

#	ARTICLE	IF	CITATIONS
73	A genetic variant conferred high expression of CAV2 promotes pancreatic cancer progression and associates with poor prognosis. <i>European Journal of Cancer</i> , 2021, 151, 94-105.	1.3	10
74	Patterns of Spread of Disease from the Pancreas. , 2010, , 259-274.		3
75	Open Pancreaticoduodenectomy Case Volume Predicts Outcome of Laparoscopic Approach. <i>Annals of Surgery</i> , 2018, 267, 552-560.	2.1	71
76	Identification of MicroRNA-21 as a Biomarker for Chemoresistance and Clinical Outcome Following Adjuvant Therapy in Resectable Pancreatic Cancer. <i>PLoS ONE</i> , 2010, 5, e10630.	1.1	261
77	Current Controversies in the Stage-Specific Multidisciplinary Management of Pancreatic Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , e157-e164.	1.8	5
78	Pathology handling of pancreatoduodenectomy specimens: Approaches and controversies. <i>World Journal of Gastrointestinal Oncology</i> , 2014, 6, 351.	0.8	8
79	Improved Diagnostic Accuracy of Pancreatic Diseases with a Combination of Various Novel Serum Biomarkers - Case Control Study from Manipal Teaching Hospital, Pokhara, Nepal. <i>Asian Pacific Journal of Cancer Prevention</i> , 2012, 13, 2171-2174.	0.5	3
80	Distal Pancreatectomy With Celiac Axis Resection for Locally Advanced Pancreatic Body Cancer – A Case Report and Literature Review. <i>In Vivo</i> , 2021, 35, 3627-3631.	0.6	0
81	Pancreatic Carcinoma. , 2009, , 1217-1232.		0
82	Preoperative Staging and Resectability Assessment of Pancreatic Cancer. , 2009, , 219-238.		0
83	Pancreatic Carcinoma. , 2010, , 111-135.		0
84	Preoperative 3-phase contrast-enhanced multidetector-row computed tomography image in evaluating resectability of pancreatic carcinoma: a comparison with postoperative pathological results. <i>Academic Journal of Second Military Medical University</i> , 2010, 30, 979-983.	0.0	0
85	Benign and Malignant Neoplasms of the Exocrine Pancreas. , 2011, , 985-1005.		0
87	Carcinoma of the Pancreas. , 2014, , 1397-1415.e7.		3
88	Staging and Determination of Resectability of Pancreatic Cancer. , 2017, , 133-138.		0
89	High Expression of MUC15 Is Correlated with Poor Prognosis of Pancreatic Cancer and Promotes Migration, Invasion, and Chemo-Resistance In Vitro. <i>Medical Science Monitor</i> , 2020, 26, e926432.	0.5	2
90	The Role of Interleukin-6 and Inflammatory Cytokines in Pancreatic Cancer-Associated Depression. <i>Cureus</i> , 2020, 12, e9969.	0.2	5
91	MODERN APPROACHES TO X-RAY DIAGNOSTICS OF NEOPLASMS OF THE PERIAMPULAR ZONE OF DUODENUM. <i>Vestnik Nacionalnogo Mediko-hirurgičeskogo Centra Im N I Pirogova</i> , 2020, 15, 107-115.	0.0	1

#	ARTICLE	IF	CITATIONS
92	Aberrant expression of microRNAs in serum may identify individuals with pancreatic cancer. <i>International Journal of Clinical and Experimental Medicine</i> , 2014, 7, 5226-34.	1.3	35
94	Multiparameter Magnetic Resonance Quantitative Evaluation of Pancreatic Cancer with Vascular Invasion. <i>BioMed Research International</i> , 2022, 2022, 1-7.	0.9	1
97	Dual-energy CT with virtual monoenergetic images and iodine maps improves tumor conspicuity in patients with pancreatic ductal adenocarcinoma. <i>Insights Into Imaging</i> , 2022, 13, .	1.6	12
98	Artificial Intelligence to Predict Lymph Node Metastasis at CT in Pancreatic Ductal Adenocarcinoma. <i>Radiology</i> , 2023, 306, 160-169.	3.6	32
99	Comprehensive machine-learning survival framework develops a consensus model in large-scale multicenter cohorts for pancreatic cancer. <i>ELife</i> , 0, 11, .	2.8	17
100	Routine neoadjuvant chemotherapy for all patients with resectable pancreatic ductal adenocarcinoma? A review of the evidence. <i>Current Opinion in Pharmacology</i> , 2022, 67, 102305.	1.7	1
101	CT-measured body composition radiomics predict lymph node metastasis in localized pancreatic ductal adenocarcinoma. <i>Discover Oncology</i> , 2023, 14, .	0.8	3